Tushar Bhikhubhai Patel - 10 Aug 2026 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Reporting relationship: 10%+ Owner
Issuer ticker: AMRX
Reported as of: 10 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Aug 2026, 18:06:35 UTC
Prior SEC filing: 17 Mar 2025
Source filing: View source filing
Reporting owner signature: Tushar Patel

Key filing fact

Tushar Bhikhubhai Patel filed Form 4 for Amneal Pharmaceuticals, Inc. (AMRX) on 12 Aug 2026.

Key facts

This page summarizes Tushar Bhikhubhai Patel's Form 4 filing for Amneal Pharmaceuticals, Inc. (AMRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 18:06.

Change

Previous filing in this sequence was filed on 17 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001745375 Primary reporting owner

Patel Tushar Bhikhubhai

Relationship: 10%+ Owner
Address: C/O TARSADIA INVESTMENTS, 520 NEWPORT CENTER DRIVE, 21ST FLOOR, NEWPORT BEACH
Signature: Tushar Patel
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMRX transaction

Class A Common Stock

Award

Transaction value
Shares: +12,763,469
Change %: +26%
Price
Shares after: 61,341,678
Date: 10 Aug 2026
Ownership: By Limited Liability Companies Controlled by Family Trusts
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC and the equityholders of Kashiv named therein (the "Sellers"), a subsidiary of the Issuer purchased (the "Acquisition") from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock ("Class A Common Stock"). Pursuant to the terms of the Purchase Agreement, a limited liability company managed by the Reporting Person received 12,763,469 shares of Class A Common Stock in the Acquisition.